LSL PHARMA GROUP ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

BOUCHERVILLE, QC, June 27, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) ("LSL Pharma" or the "Corporation"), a Canadian integrated pharmaceutical company, today announced the voting results of its annual general and special meeting of shareholders held today in Boucherville, Québec at the Corporation's headquarters (the "Meeting").

Election of Directors

Mr. François Roberge, Mr. Frank Dellafera, Mr. Mario Paradis and Mr. Louis Laflamme were elected directors of the Corporation to hold office until the next annual meeting of shareholders or until their successors are appointed or elected.

Each of the remaining director nominees have received less than 50% of the votes cast in favour of their election. At the Corporation's request, these nominees may continue in office, for a maximum of 90 days for transition purposes, after which the Board will accept their resignations.

Full voting results are available on SEDAR+ at www.sedarplus.ca.

Appointment of Auditors

Audacie Inc. has been re-appointed as auditors of the Corporation for the ensuing year and the directors are authorized to fix their remuneration.

Approval of Stock Option Plan

The current 10% rolling stock option plan of the Corporation has been re-approved until the next annual meeting of shareholders.

Further disclosure on the matters approved at the Meeting, including full voting results, can be found in the notice and accompanying management information circular filed in respect of the Meeting and available on SEDAR+ at www.sedarplus.ca.

ABOUT LSL PHARMA GROUP INC.

LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Companies forming part of LSL Pharma Group include Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Santé Inc. and Dermolab Pharma Ltée. For further information, please visit our website at www.groupelslpharma.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements as defined under applicable Canadian securities legislation. Forward-looking statements can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "continue" or similar expressions. Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Corporation's ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, those identified in the Corporation's filings with Canadian securities regulatory authorities, such as legislative or regulatory developments, increased competition, technological change and general economic conditions. All forward-looking statements made herein should be read in conjunction with such documents.

Readers are cautioned not to place undue reliance on forward-looking statements. No assurance can be given that any of the events referred to in the forward-looking statements will transpire, and if any of them do, the actual results, performance or achievements of the Corporation may differ materially from those expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. The Corporation does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) have reviewed or accept responsibility for the adequacy or accuracy of this release.

SOURCE Groupe LSL PHARMA INC.